Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jun 13, 2025 · Filed Jun 17, 2025
The CEO of Medifast paid $5K out of pocket for Medifast shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$5,003
Shares × reported transaction price
<$25K
+0.3%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the CEO's reported total pay for fiscal 2024 ($5.61M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-06. The proxy does not tag the CEO's name, so the match rests on the Form 4 title only. A size comparison, not a judgement
46 days after results of Apr 28, 2025, 52 days before results of Aug 4, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −7.4% | +1.6% | −9.0% |
| 30 days | −6.6% | +5.0% | −11.6% |
| 90 days | +1.3% | +10.5% | −9.1% |
| 180 days | −15.3% | +13.9% | −29.3% |
| 365 days | −22.1% | +25.0% | −47.1% |
Past results only. Not a forecast.